WO2022176994A1 - 改変されたα1,2-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 - Google Patents
改変されたα1,2-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 Download PDFInfo
- Publication number
- WO2022176994A1 WO2022176994A1 PCT/JP2022/006790 JP2022006790W WO2022176994A1 WO 2022176994 A1 WO2022176994 A1 WO 2022176994A1 JP 2022006790 W JP2022006790 W JP 2022006790W WO 2022176994 A1 WO2022176994 A1 WO 2022176994A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- seq
- protein
- sequence represented
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract description 93
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 101710098620 Alpha-1,2-fucosyltransferase Proteins 0.000 title claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 34
- 102000035118 modified proteins Human genes 0.000 title abstract 2
- 108091005573 modified proteins Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 176
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 169
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 134
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 53
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 53
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 53
- 244000005700 microbiome Species 0.000 claims abstract description 42
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 12
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 12
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims description 244
- 235000018102 proteins Nutrition 0.000 claims description 160
- 108020004414 DNA Proteins 0.000 claims description 146
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 94
- 238000006467 substitution reaction Methods 0.000 claims description 80
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 30
- 229930064664 L-arginine Chemical class 0.000 claims description 29
- 235000014852 L-arginine Nutrition 0.000 claims description 29
- 108020004511 Recombinant DNA Proteins 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 229960003767 alanine Drugs 0.000 claims description 21
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical class OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 18
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 17
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 17
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-Lysine Natural products NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 15
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- 108010021466 Mutant Proteins Proteins 0.000 claims description 12
- 102000008300 Mutant Proteins Human genes 0.000 claims description 12
- 239000012736 aqueous medium Substances 0.000 claims description 12
- 229960002429 proline Drugs 0.000 claims description 12
- 229960001153 serine Drugs 0.000 claims description 12
- 229930182821 L-proline Natural products 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 235000019766 L-Lysine Nutrition 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 150000008534 L-alanines Chemical class 0.000 claims description 6
- 229930182844 L-isoleucine Natural products 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 5
- 239000004395 L-leucine Substances 0.000 claims description 5
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 5
- 150000008545 L-lysines Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 description 64
- 235000014633 carbohydrates Nutrition 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 48
- 241000588724 Escherichia coli Species 0.000 description 47
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 32
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 32
- 239000012634 fragment Substances 0.000 description 27
- 235000000346 sugar Nutrition 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 14
- 238000011144 upstream manufacturing Methods 0.000 description 14
- PHTAQVMXYWFMHF-GJGMMKECSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](NC(C)=O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O PHTAQVMXYWFMHF-GJGMMKECSA-N 0.000 description 13
- 229960001375 lactose Drugs 0.000 description 13
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 239000013611 chromosomal DNA Substances 0.000 description 11
- 101150001899 lacY gene Proteins 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 101150066555 lacZ gene Proteins 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 8
- 101150100260 wcaM gene Proteins 0.000 description 8
- 101100156625 Escherichia coli (strain K12) wcaJ gene Proteins 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 241000588722 Escherichia Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000590006 Helicobacter mustelae Species 0.000 description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229960003104 ornithine Drugs 0.000 description 4
- -1 phosphomannommutase Proteins 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 101150025220 sacB gene Proteins 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical group OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 3
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 3
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 3
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 3
- 238000012269 metabolic engineering Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 2
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000423333 Bacteroides fragilis NCTC 9343 Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 101100156626 Escherichia coli (strain K12) wcaK gene Proteins 0.000 description 2
- 101100264107 Escherichia coli (strain K12) wzxC gene Proteins 0.000 description 2
- 241001452028 Escherichia coli DH1 Species 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- 241000901842 Escherichia coli W Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241001674329 Helicobacter pylori 26695 Species 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 2
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FYGDTMLNYKFZSV-SKWQFERISA-N alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-SKWQFERISA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- 108010060845 lactose permease Proteins 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 101150098466 rpsL gene Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150043455 wcaL gene Proteins 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- YOFPFYYTUIARDI-ZCFIWIBFSA-N (2r)-2-aminooctanedioic acid Chemical group OC(=O)[C@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-ZCFIWIBFSA-N 0.000 description 1
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 101900040182 Bacillus subtilis Levansucrase Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100024515 GDP-L-fucose synthase Human genes 0.000 description 1
- 108030006298 GDP-L-fucose synthases Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- BRHHWBDLMUBZQQ-JZEMXWCPSA-N Lactodifucotetraose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H](O)[C@H](O)CO)[C@H](C=O)O[C@@H]1[C@H](O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 BRHHWBDLMUBZQQ-JZEMXWCPSA-N 0.000 description 1
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 1
- 108010070158 Lactose synthase Proteins 0.000 description 1
- 108010038016 Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 1
- 108091022912 Mannose-6-Phosphate Isomerase Proteins 0.000 description 1
- 102000048193 Mannose-6-phosphate isomerases Human genes 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000235005 Schwanniomyces occidentalis var. occidentalis Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001634922 Tausonia pullulans Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000005061 Vibrio cholerae O22 Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 1
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 241000186254 coryneform bacterium Species 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- RQNFGIWYOACERD-UHFFFAOYSA-N lacto-N-Difucosylhexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O RQNFGIWYOACERD-UHFFFAOYSA-N 0.000 description 1
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 description 1
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- SCVOEYLBXCPATR-UHFFFAOYSA-L manganese(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O SCVOEYLBXCPATR-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 101150117960 rcsA gene Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 229940098362 serratia marcescens Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 101150018163 wcaJ gene Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01069—Galactoside 2-alpha-L-fucosyltransferase (2.4.1.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- the present invention relates to a protein having a modified ⁇ 1,2-fucosyltransferase activity and a method for producing a fucose-containing carbohydrate using the protein or a microorganism capable of producing the protein.
- HMOs Human milk oligosaccharides
- Non-Patent Document 2 Among carbohydrates known as HMOs, fucose-containing carbohydrates such as 2'-fucosyllactose account for about 60% of the total HMOs, and the functionality of these carbohydrates has attracted attention (Non-Patent Document 2).
- Non-Patent Document 4 ⁇ 1,2-fucosyltransferase derived from Helicobacter pylori is widely used in methods for producing fucose-containing carbohydrates by enzymatic reaction or fermentation production (Non-Patent Documents 2 and 3), but the fucose transfer The problem is that the activity of the enzyme is insufficient (Non-Patent Document 4).
- Non-Patent Document 5 ⁇ 1,2-fucosyltransferase derived from Bacteroides fragilis
- Patent Document 1 ⁇ 1,2-fucosyltransferase derived from Helicobacter mustelae
- the purpose of the present invention is to provide a protein having a modified ⁇ 1,2-fucosyltransferase activity and a method for producing a fucose-containing carbohydrate using the protein or a microorganism capable of producing the protein.
- the present invention relates to the following. 1. Amino acid residues corresponding to the 9th, 68th, 75th, 86th and 238th amino acid sequences of the amino acid sequence represented by SEQ ID NO: 2 in the amino acid sequence of the protein according to any one of [1] to [3] below A protein consisting of an amino acid sequence containing substitutions of one or more amino acid residues selected from the group consisting of groups to other amino acid residues, and A protein having improved ⁇ 1,2-fucosyltransferase activity compared to the original protein according to any one of [1] to [3] below.
- a protein consisting of the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8 or 10
- a mutant protein consisting of an amino acid sequence in which amino acids are deleted, substituted, inserted and/or added, and having ⁇ 1,2-fucosyltransferase activity
- a homologous protein consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by and having ⁇ 1,2-fucosyltransferase activity.
- the protein according to 1 above which consists of an amino acid sequence containing a substitution of a group for another amino acid residue.
- amino acid sequence of the protein according to any one of [1] to [3] above comprises an amino acid sequence containing at least one substitution selected from the following [1a] to [1e]: protein.
- any one of the above 1 to 3, wherein the amino acid sequence of the protein according to any one of the above [1] to [3] comprises an amino acid sequence containing at least one substitution selected from the following [2a] to [2e] 1.
- the protein according to 1. [2a] substitution of L-arginine for the amino acid residue corresponding to position 9 in the amino acid sequence represented by SEQ ID NO: 2 [2b] replacement of the amino acid residue corresponding to position 68 in the amino acid sequence represented by SEQ ID NO: 2
- substitution with L-arginine [2c]
- substitution of the corresponding amino acid residue with L-serine [2e] Substitution of the amino acid residue corresponding to position 238 in the amino acid sequence represented by SEQ ID NO: 2 with L-alanine5.
- an amino acid sequence comprising a substitution of L-arginine for the amino acid residue corresponding to position 9 in the amino acid sequence represented by SEQ ID NO: 2 5.
- 8. A DNA encoding the protein according to any one of 1 to 7 above.
- a method for producing a fucose-containing saccharide which comprises culturing a microorganism capable of producing the protein according to any one of 1 to 7 above in a medium to produce the fucose-containing saccharide in the culture. 12.
- the microorganism having the ability to produce the protein according to any one of 1 to 7 above is cultured in a medium, and the resulting culture or a processed product of the culture is used as an enzyme source, the enzyme source, GDP-fucose and
- a method for producing a fucose-containing saccharide comprising allowing an acceptor saccharide to exist in an aqueous medium and producing a fucose-containing saccharide in the aqueous medium. 13.
- a method for producing a fucose-containing carbohydrate using a protein having modified ⁇ 1,2-fucosyltransferase activity and the protein or a microorganism capable of producing the protein is provided.
- the protein of the present invention is a protein according to any one of (1) to (7) below.
- (1) Corresponding to the 9th, 68th, 75th, 86th and 238th amino acid sequences of the amino acid sequence represented by SEQ ID NO: 2 in the amino acid sequence of the protein according to any one of [1] to [3] below
- a protein consisting of an amino acid sequence containing substitutions of one or more amino acid residues selected from the group consisting of the amino acid residues that correspond to other amino acid residues, and A protein having improved ⁇ 1,2-fucosyltransferase activity compared to the original protein according to any one of [1] to [3].
- a mutant protein consisting of an amino acid sequence in which amino acids are deleted, substituted, inserted and/or added, and having ⁇ 1,2-fucosyltransferase activity [3] SEQ ID NO: 2, 4, 6, 8 or 10 (2) Any of the above [1] to [3], which is a homologous protein consisting of an amino acid sequence having 80% or more identity with the amino acid sequence represented by and having ⁇ 1,2-fucosyltransferase activity In the amino acid sequence of the protein according to or 1, from the amino acid residues corresponding to the 9th, 68th, 75th, 86th and 238th amino acid sequences represented by SEQ ID NO: 2 to other amino acid residues
- amino acid residues to be used are the 9th, 68th, 75th, 86th and 238th amino acid residues in the amino acid sequence of SEQ ID NO: 2 when the amino acid sequence of the original protein and the amino acid sequence of SEQ ID NO: 2 are aligned. Refers to each amino acid residue that aligns to the same position as the amino acid residue.
- amino acid residues to be used include the following. (i) When the original protein is a protein consisting of the amino acid sequence represented by SEQ ID NO: 2, the 9th, 68th, 75th, 86th and 86th amino acid sequences represented by SEQ ID NO: 2, respectively 238th amino acid residue.
- amino acid sequence represented by SEQ ID NO:8 there is no amino acid residue corresponding to position 86 in the amino acid sequence represented by SEQ ID NO:2.
- substitution of one or more amino acid residues selected from the group consisting of groups with other amino acid residues is, for example, the substitution with other amino acid residues [1] It can be confirmed by aligning the amino acid sequence of the protein according to any one of [3] with the amino acid sequence of the original protein.
- Alignment of amino acid sequences can be created using, for example, the known alignment program ClustalW [Nucelic Acids Research 22, 4673, (1994)].
- ClustalW for example, http://www. ebi.ac. Available from uk/clustalw/ (European Bioinformatics Institute). Default values, for example, can be used for parameters when creating an alignment using ClustalW.
- Natural amino acids include L-alanine, L-asparagine, L-aspartic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-arginine, L -methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine and the like.
- Group A leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, o-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine
- Group B aspartic acid, glutamic acid, isoaspartic acid, Isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid
- Group C asparagine, glutamine
- D lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid
- Group E proline, 3 -Hydroxyproline, 4-hydroxyproline
- F group serine, threonine, homoserine
- G group phenylalanine
- substitution of an amino acid residue with another amino acid residue in the amino acid sequence of the protein according to any one of [1] to [3] above is , preferably at least one selected from the following [a] to [e], and the other amino acid residue is more preferably an L-form.
- substitution of an amino acid residue with another amino acid residue in the amino acid sequence of the protein according to any one of [1] to [3] above preferably includes at least one selected from the following [1a] to [1e].
- the amino acid sequence represented by SEQ ID NO: 2, 9th, 68th Of the one or more amino acid residues selected from the group consisting of the amino acid residues corresponding to the 75th, 86th and 238th amino acids, at least one or more, preferably two or more amino acid residues are preferably substituted.
- [A ] and [B] are more preferably included.
- [A] Substitution of the amino acid residue corresponding to the 9th position of the amino acid sequence represented by SEQ ID NO: 2 with another amino acid, preferably the amino acid residues described in the above group D (lysine, arginine, ornithine, 2, 4-diaminobutanoic acid, 2,3-diaminopropionic acid) with 1 selected from, more preferably with L-arginine
- [C ] is particularly preferred. [C] substitution of the amino acid residue corresponding to position 9 in the amino acid sequence represented by SEQ ID NO: 2 with L-arginine, and amino acid residue corresponding to position 238 in the amino acid sequence represented by SEQ ID NO: 2 to L - substitution to alanine
- the ⁇ 1,2-fucosyltransferase activity is the activity of transferring fucose to the galactose residue of the acceptor sugar via an ⁇ 1,2 bond using GDP-fucose and an acceptor sugar as substrates to produce a fucose-containing sugar.
- Acceptor carbohydrates include carbohydrates containing oligosaccharides having galactose at the non-reducing end, preferably lactose, globotriose, N-acetyllactosamine, lacto-N-tetraose, and lacto-N-neotetraose at the non-reducing end. , Lewis X, or Lewis a structure, more preferably lactose, globotriose, N-acetyllactosamine, lacto-N-tetraose, lacto-N-neotetraose, Lewis X, or Lewis a et al.
- fucose-containing carbohydrates obtained using the above-mentioned acceptor carbohydrate as a substrate examples include 2′-fucosyllactose, lacto-N-fucopentaose I, lactodifucotetraose, lacto-N-difucohexaose I, and lacto- N-neofucopentaose I and the like can be mentioned.
- the fact that the protein according to any one of (1) to (7) above has improved ⁇ 1,2-fucosyltransferase activity compared to the original protein can be confirmed, for example, by the following method.
- a microorganism that does not have ⁇ 1,2-fucosyltransferase activity such as a microorganism obtained by transforming Escherichia coli strain W3110, is cultured with the recombinant DNA, and cells containing the protein are obtained from the culture. Prepare the extract.
- the cell extract containing the protein is brought into contact with an aqueous solution containing GDP-fucose as a substrate and receptor saccharides to produce fucose-containing saccharides in the aqueous solution.
- the fucose-containing carbohydrates in the reaction solution were detected using a saccharide analyzer described later, and the amounts of the carbohydrates produced were compared to find that the ⁇ 1,2-fucosyltransferase activity of the protein was higher than that of the original protein. I can confirm that it is improving.
- Mutant protein refers to a protein obtained by artificially deleting or substituting amino acid residues in the original protein, or artificially inserting or adding amino acid residues into the protein.
- deletion, substitution, insertion or addition of amino acids may be deletion, substitution, insertion or addition of 1 to 20 amino acids at any position in the same sequence.
- Amino acids to be substituted, inserted or added may be natural or non-natural.
- naturally occurring amino acids include the aforementioned naturally occurring amino acids.
- Homologous proteins refer to a group of proteins derived from proteins of the same evolutionary origin, which are proteins possessed by organisms that exist in nature. Homologous proteins are similar in structure and function to each other.
- the above mutant protein or homologous protein has ⁇ 1,2-fucosyltransferase activity can be confirmed, for example, by the following method.
- a recombinant DNA having a DNA encoding a mutant protein or a homologous protein whose activity is to be confirmed is prepared by the method described below.
- a microorganism that does not have ⁇ 1,2-fucosyltransferase activity such as a microorganism obtained by transforming Escherichia coli strain W3110, is cultured with the recombinant DNA, and cells containing the protein are obtained from the culture. Prepare the extract.
- the cell extract containing the protein is brought into contact with an aqueous solution containing GDP-fucose as a substrate and receptor saccharides to produce fucose-containing saccharides in the aqueous solution.
- an aqueous solution containing GDP-fucose as a substrate and receptor saccharides to produce fucose-containing saccharides in the aqueous solution.
- proteins of the present invention include proteins consisting of the amino acid sequences set forth in SEQ ID Nos: 51, 52, 53, and 54.
- DNA of the present invention is DNA encoding the protein described in any one of (1) to (7) above.
- Specific examples of the DNA of the present invention include any one of the following (8) to (13).
- L-arginine for the amino acid residue L-proline for the amino acid residue corresponding to the 75th amino acid residue, L-serine for the amino acid residue corresponding to the 86th amino acid residue, or L-alanine for the amino acid residue corresponding to the 238th amino acid residue.
- a DNA that encodes a protein consisting of an amino acid sequence (10) The DNA according to (8) above, wherein in the amino acid sequence encoded by the amino acid sequence, the amino acid residue corresponding to position 9 in the amino acid sequence represented by SEQ ID NO: 2 is substituted with L-arginine.
- DNA encoding a protein consisting of (11) The DNA according to (8) above, wherein in the amino acid sequence encoded by the amino acid sequence, the amino acid residue corresponding to position 238 in the amino acid sequence represented by SEQ ID NO: 2 is substituted with L-alanine.
- DNA encoding a protein consisting of (12) The DNA according to (8) above, wherein in the amino acid sequence encoded by the amino acid sequence, the amino acid residue corresponding to the 9th position in the amino acid sequence represented by SEQ ID NO: 2 is L-arginine, and the 238th position
- (13) DNA having the nucleotide sequence represented by SEQ ID NO: 11, 12, 13 or 14;
- hybridize means a step in which DNA hybridizes to a DNA having a specific base sequence or a part of the DNA. Therefore, the DNA having the specific nucleotide sequence or the nucleotide sequence of the DNA hybridizing to a part of the DNA is useful as a probe for Northern or Southern blot analysis, or can be used as an oligonucleotide primer for PCR analysis. It may be the same DNA.
- DNAs used as probes include, for example, DNAs of at least 100 bases or more, preferably 200 bases or more, and more preferably 500 bases or more.
- DNAs used as primers include, for example, DNAs of at least 10 bases or more, preferably 15 bases or more.
- DNA that hybridizes under stringent conditions can also be obtained by following the instructions attached to the commercially available hybridization kit.
- Commercially available hybridization kits include, for example, a random primed DNA labeling kit (manufactured by Roche Diagnostics) in which probes are prepared by the random prime method and hybridized under stringent conditions.
- the above stringent conditions are, for example, DNA-immobilized filters and probe DNAs mixed with 50% formamide, 5 ⁇ SSC (750 mM sodium chloride, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6). ), 5 ⁇ Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/L of denatured salmon sperm DNA after overnight incubation at 42° C., followed by, for example, 0.2 ⁇ SSC solution at about 65° C. conditions in which the filter is washed.
- 5 ⁇ SSC 750 mM sodium chloride, 75 mM sodium citrate
- 50 mM sodium phosphate pH 7.6
- 5 ⁇ Denhardt's solution 10% dextran sulfate
- 20 ⁇ g/L of denatured salmon sperm DNA after overnight incubation at 42° C.
- 0.2 ⁇ SSC solution at about 65° C. conditions in which the filter is washed.
- the various conditions described above can also be set by adding or changing blocking reagents used to suppress background in hybridization experiments. Addition of blocking reagents as described above may be accompanied by alteration of the hybridization conditions in order to match the conditions.
- Examples of the DNA that can hybridize under the above stringent conditions include SEQ ID NOs: 1, 3, 5, 7 and 9 when calculated based on the above parameters using programs such as BLAST and FASTA.
- a DNA consisting of a base sequence having at least 95% or more, preferably 97% or more, more preferably 98% or more, and most preferably 99% or more identity with the indicated base sequence.
- the DNA of the present invention for example, using a DNA encoding a protein consisting of an amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8 or 10, the 9th position of SEQ ID NO: 2 located on the DNA, For example, Molecular Cloning 4th Edition (Cold Spring Harbor Laboratory Press (2012)) and Current Protocols in Molecular Biology (JOHN WILEY & SONS, INC.). It can be obtained by substituting the encoding base sequence. Alternatively, the DNA of the present invention can also be obtained by using PrimeSTAR Mutagenesis Basal Kit (manufactured by Takara Bio Inc.).
- a mutein comprising an amino acid sequence in which 1 to 20 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence represented by, for example, SEQ ID NO: 2, 4, 6, 8 or 10 by the same method and having ⁇ 1,2-fucosyltransferase activity, the amino acid sequence of the mutant protein and the amino acid represented by SEQ ID NO: 2, 4, 6, 8 or 10 as the base thereof
- a DNA encoding a homologous protein consisting of an amino acid sequence having 90% or more identity with the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8 or 10 and having ⁇ 1,2-fucosyltransferase activity is used. Then, when the amino acid sequence of the homologous protein and its original amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8 or 10 are aligned by the method of 1 above, in the amino acid sequence of the homologous protein, the sequence Mutation in the base sequence of the portion encoding one or more amino acid residues selected from the group consisting of amino acid residues corresponding to the 9th, 68th, 75th, 86th and 238th amino acid residues of number 2 It can also be obtained by installing
- the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 2 can be obtained, for example, by using a probe that can be designed based on the base sequence of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 2.
- a probe that can be designed based on the base sequence of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 2.
- Preferably by Southern hybridization to the chromosomal DNA library of Helicobacter genus, more preferably Helicobacter mustelae ATCC43772 strain, or using a primer DNA that can be designed based on the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 2 It can be obtained by PCR [PCR Protocols, Academic Press (1990)] using the chromosomal DNA of Helicobacter mustelae ATCC 43772 strain as a template.
- the DNA encoding the amino acid sequence represented by SEQ ID NO: 4 can be obtained, for example, by using a probe that can be designed based on the base sequence of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 4, using a microorganism, preferably Helicobacter.
- Helicobacter pylori ATCC700392 by Southern hybridization to the chromosomal DNA library of the genus, more preferably Helicobacter pylori ATCC700392 strain, or using a primer DNA that can be designed based on the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 4 It can be obtained by PCR using the chromosomal DNA of the strain as a template.
- Specific examples of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO:4 include DNA having the nucleotide sequence represented by SEQ ID NO:3.
- the DNA encoding the amino acid sequence represented by SEQ ID NO: 6 can be obtained, for example, by using a probe that can be designed based on the base sequence of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 6, and by using a microorganism, preferably Escherichia. genus, more preferably Escherichia coli O126 strain. It can be obtained by PCR using the chromosomal DNA of Escherichia coli O126 strain as a template.
- Specific examples of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO:6 include DNA having the nucleotide sequence represented by SEQ ID NO:5.
- the DNA encoding the amino acid sequence represented by SEQ ID NO: 8 can be obtained, for example, by using a probe that can be designed based on the base sequence of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 8, and by using a microorganism, preferably Bacteroides.
- Bacteroides fragilis ATCC 25285 by Southern hybridization to the chromosomal DNA library of the genus, more preferably Bacteroides fragilis ATCC 25285 strain, or using primer DNA that can be designed based on the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 8 It can be obtained by PCR using the chromosomal DNA of the strain as a template.
- the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO:8 specifically includes DNA having the base sequence represented by SEQ ID NO:7.
- the DNA encoding the amino acid sequence represented by SEQ ID NO: 10 can be obtained by using a probe that can be designed based on the nucleotide sequence of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 10, and extracting the DNA from a microorganism, preferably Vibrio. genus, more preferably Vibrio cholerae (Vibrio cholerae) O22 strain chromosomal DNA library, or by using a primer DNA that can be designed based on the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 10 It can be obtained by PCR using the chromosomal DNA of the Vibrio cholerae O22 strain as a template.
- a specific example of the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO:10 is a DNA having the base sequence represented by SEQ ID NO:9.
- a DNA encoding a mutant protein consisting of a sequence and having ⁇ 1,2-fucosyltransferase activity can be obtained, for example, by using a DNA consisting of a nucleotide sequence represented by SEQ ID NO: 1, 3, 5, 7 or 9 as a template. can be obtained by subjecting it to error-prone PCR or the like.
- a partially specific mutagenesis method by PCR using a set of PCR primers each having at their 5' end a nucleotide sequence designed to introduce the desired mutation (deletion, substitution, insertion or addition) [ Gene, 77, 51 (1989)], 1 to 20 amino acids are deleted, substituted, or A DNA encoding a mutant protein comprising an inserted or added amino acid sequence and having ⁇ 1,2-fucosyltransferase activity can be obtained.
- the DNA can also be obtained by following the instructions attached to the commercially available partial-specific mutagenesis kit.
- a commercially available partial-specific mutagenesis kit for example, PrimeSTAR (registered trademark) Mutagenesis Basal Kit (manufactured by Takara Bio Inc.) that can introduce mutation (deletion, substitution, insertion or addition) at the position where the desired mutation is to be introduced is available. mentioned.
- a pair of mutagenesis primers having a 15-base overlap on the 5' side is designed. do. At this time, the overlapping portion contains the desired mutation.
- PCR is performed using a plasmid having a nucleotide sequence to be mutated as a template. By transforming the amplified fragment thus obtained into Escherichia coli, a plasmid having the nucleotide sequence into which the desired mutation has been introduced can be obtained.
- a DNA encoding a homologous protein having fucosyltransferase activity can be obtained, for example, by the following method.
- a nucleotide sequence having an identity of 99% or more is searched, and using a probe DNA or primer DNA that can be designed based on the nucleotide sequence or amino acid sequence obtained by the search, and a microorganism having the DNA, the above-mentioned
- a DNA encoding the homologous protein can be obtained by a method similar to the method for obtaining the DNA encoding the protein consisting of the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8 or 10.
- base sequences and amino acid sequences can be determined by the same method as 1 above.
- the DNA of the present invention obtained by the above method may be used as it is, or may be cleaved with an appropriate restriction enzyme or the like, incorporated into a vector by a conventional method, and the resulting recombinant DNA introduced into a host cell.
- Sequence analysis methods such as the dideoxy method [Proc. Nat. Acad. Sci. , USA, 74, 5463 (1977)], or using a base sequence analyzer such as Applied Biosystems 3500 Genetic Analyzer or Applied Biosystems 3730 DNA Analyzer (both manufactured by Thermo Fisher Scientific). can determine the base sequence of the DNA.
- Vectors that can be used for determining the nucleotide sequence of the DNA of the present invention include, for example, pBluescriptII KS (+), pPCR-Script Amp SK (+) (all manufactured by Agilent Technologies), pT7Blue (Merck Millipore company), pCRII (manufactured by Thermo Fisher Scientific), pCR-TRAP (manufactured by Gene Hunter), and pDIRECT [Nucleic Acids Res. , 18, 6069 (1990)].
- Any host cell can be used as long as the vector can be introduced and proliferated. Examples include Escherichia coli DH5 ⁇ , Escherichia coli HST08 Premium, Escherichia coli HST02, Escherichia coli HST04 dam ⁇ /dcm ⁇ , and Escherichia coli JM109.
- any method for introducing DNA into the host cell can be used.
- a method using calcium ions [Proc. Natl. Acad. Sci. , USA, 69, 2110 (1972)]
- protoplast method Japanese Patent Laid-Open No. 63-248394
- electroporation method [Nucleic Acids Res. , 16, 6127 (1988)].
- full-length DNA can be obtained by Southern hybridization method etc. for the chromosomal DNA library using the partial length DNA as a probe.
- the target DNA can be prepared by chemical synthesis using the NTS M series DNA synthesizer manufactured by Nippon Techno Service Co., Ltd., etc.
- the recombinant DNA of the present invention is a DNA capable of autonomous replication in a host cell, wherein the DNA of the present invention is incorporated into an expression vector containing a promoter at a position where the DNA of the present invention can be transcribed in 2 above. It is the DNA that exists.
- a DNA that can be integrated into the chromosome in a host cell and that has the DNA of the present invention is also the recombinant DNA of the present invention.
- the recombinant DNA is a recombinant DNA that can be integrated into the chromosome, it may not contain a promoter.
- the recombinant DNA of the present invention is a recombinant DNA composed of a promoter, a ribosome binding sequence, the DNA of the present invention described in 2 above, and a transcription termination sequence. is preferred. Furthermore, a gene controlling a promoter may be included.
- the distance between the Shine-Dalgarno sequence, which is the ribosome binding sequence, and the initiation codon is preferable to adjust the distance between the Shine-Dalgarno sequence, which is the ribosome binding sequence, and the initiation codon to an appropriate distance, for example, 6 to 18 bases.
- a transcription termination sequence is not necessarily required for expression of the DNA of the present invention, but it is preferable to place a transcription termination sequence immediately below the structural gene.
- expression vectors include pColdI, pSTV28, pUC118 (all manufactured by Takara Bio), pET21a, pCDF-1b, and pRSF.
- pKYP200 Agric. Biol. Chem. , 48, 669 (1984)]
- pLSA1 Agric. Biol. Chem. , 53, 277 (1989)]
- pGEL1 Proc. Natl. Acad. Sci. , USA, 82, 4306 (1985)]
- pTrS30 prepared from Escherichia coli JM109/pTrS30 (FERM BP-5407)
- pTrS32 prepared from Escherichia coli JM109/pTrS32 (FERM BP-5408)]
- pTKNTK31 Irnamplied MICROBIOLOGY, 2007, Vol. 73, No.
- Any promoter that functions in the cells of microorganisms belonging to the genus Escherichia can be used when the above expression vector is used.
- Examples include trp promoter, gapA promoter, lac promoter, PL promoter, PR promoter, Promoters derived from Escherichia coli, phages, etc., such as the PSE promoter, can be used.
- Artificially designed and modified promoters such as two trp promoters in series, tac promoter, trc promoter, lacT5 promoter, lacT7 promoter, and let I promoter can also be used.
- expression vectors include, for example, pCG1 (Japanese Patent Laid-Open No. 57-134500), pCG2 (Japanese Patent Laid-Open No. 58- 35197), pCG4 (Japanese Patent Laid-Open No. 57-183799), pCG11 (Japanese Patent Laid-Open No. 57-134500), pCG116, pCE54, pCB101 (both Japanese Patent Laid-Open No. 58-105999 publication), pCE51, pCE52, and pCE53 [all of which are Molecular and General Genetics, 196, 175 (1984)].
- any promoter that functions in coryneform bacterium cells may be used as the promoter when using the above expression vector.
- the P54-6 promoter [Appl. Microbiol. Biotechnol. , 53, p674-679 (2000)] can be used.
- expression vectors include, for example, YEp13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419), pHS19, and pHS15.
- Any promoter can be used when the expression vector is used, as long as it functions in cells of yeast strains. Examples include PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal1 promoter, gal10 promoter, Promoters such as heat shock polypeptide promoter, MF ⁇ 1 promoter, and CUP1 promoter are included.
- the recombinant DNA of the present invention can be produced, for example, by treating the DNA fragment prepared by the method 2 above with a restriction enzyme and inserting it downstream of the promoter of the appropriate expression vector.
- the expression level of the protein encoded by the DNA can be improved.
- Information on codon usage in host cells is available through public databases.
- the transformant of the present invention is a transformant obtained by transforming a host cell with the recombinant DNA containing the DNA of the present invention described in 2 above.
- Host cells into which the recombinant DNA of the present invention is introduced may be any of prokaryotes, yeast, animal cells, insect cells, plant cells, etc., preferably prokaryotes or yeast strains, more preferably , Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, etc., or Saccharomyces, Schizosaccharomyces, Kluyveromyces, Trichosporon , Siwaniomyces, Pichia, or Candida, most preferably Escherichia coli BL21 codon plus, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue (all manufactured by Agilent Technologies), Escherichia coli BL21(DE3)pLysS( ⁇ ) ⁇ Escherichia coli DH5 ⁇ Escherichia coli HST08 Premium ⁇ Escherichia coli HST02 ⁇ E
- the above Escherichia coli KY3591 is located at 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan (zip code 292-0818). ).
- the date of receipt (deposit date) is November 18, 2019, and the deposit number is NITE BP-03062.
- a breeding strain artificially endowed or enhanced with the ability to produce GDP-fucose, which is a reaction substrate of ⁇ 1,2-fucosyltransferase, can be used.
- Methods for artificially imparting or enhancing the ability to produce GDP-fucose from sugar to a microorganism used as a host cell include (a) at least one mechanism that controls the biosynthetic pathway for producing GDP-fucose from sugar; (b) a method of enhancing the expression of at least one of the enzymes involved in the biosynthetic pathway that produces GDP-fucose from sugars; (c) a biosynthetic pathway that produces GDP-fucose from sugars (d) at least one metabolic pathway branching from a biosynthetic pathway that produces GDP-fucose from sugar to a metabolite other than the target substance; methods of weakening or blocking, and the like, and the above known methods can be used alone or in combination.
- Mechanism that controls the biosynthetic pathway that produces GDP-fucose from sugar include known mechanisms such as the control mechanism by transcriptional regulatory factors (RcsA, etc.) that are involved in the regulation of the biosynthetic pathway.
- RcsA transcriptional regulatory factors
- enzymes involved in the biosynthetic pathway that produces GDP-fucose from sugar include mannose-6-phosphate isomerase, phosphomannommutase, mannose-1-phosphate guanylyltransferase, GDP-mannose- Known enzymes such as 4,6-dehydratase and GDP-L-fucose synthase can be mentioned.
- metabolic pathway branching from the biosynthetic pathway that produces GDP-fucose from sugar to metabolites other than the target substance include known metabolic pathways such as the metabolic pathway from GDP-fucose to colanic acid. be done.
- a breeding strain artificially endowed or enhanced with the ability to supply receptor carbohydrates, which are reaction substrates of ⁇ 1,2-fucosyltransferase, can also be used.
- Methods for artificially imparting or enhancing the ability to supply receptor carbohydrates to microorganisms used as host cells include (a) at least one mechanism that regulates the biosynthetic pathway for producing receptor carbohydrates from sugars; (b) a method of enhancing the expression of at least one enzyme involved in a biosynthetic pathway that produces an acceptor carbohydrate from a sugar; (c) a biosynthesis that produces an acceptor carbohydrate from a sugar (d) reducing or eliminating at least one of the mechanisms that degrade the receptor carbohydrate; (f) a method of increasing the copy number of at least one gene encoding an enzyme involved in cellular uptake of a receptor carbohydrate; (g) methods of weakening or blocking at least one of the metabolic pathways branching from the receptor carbohydrate to metabolites other than the target substance, and the like, and the above known methods can be used alone or in combination.
- enzymes involved in biosynthetic pathways that produce acceptor carbohydrates from sugars include known enzymes such as enzymes that have lactose synthase activity that produces lactose using glucose and UDP-galactose as substrates.
- enzymes that have lactose synthase activity that produces lactose using glucose and UDP-galactose as substrates include known enzymes such as ⁇ -galactosidase, which catalyzes the hydrolysis of lactose to produce glucose and galactose.
- enzymes involved in intracellular uptake of receptor carbohydrates include known enzymes such as lactose permease, which is involved in intracellular uptake of lactose.
- Specific examples of the method of imparting or enhancing the ability to supply receptor carbohydrates include a method of reducing or inactivating the activity of ⁇ -galactosidase by genetic manipulation (Metabolic Engineering (2017) 41: 23-38). , known methods.
- Methods for introducing the recombinant DNA of 3 above as an autonomously replicable plasmid in host cells include, for example, the above-mentioned method using calcium ions, the protoplast method, the electroporation method, and the spheroplast method [Proc. Natl. Acad. Sci. , USA, 81, 4889 (1984)], the lithium acetate method [J. Bacteriol. , 153, 163 (1983)].
- Methods for integrating recombinant DNA into the chromosome of host cells include, for example, homologous recombination.
- the homologous recombination method includes, for example, a method using a plasmid for homologous recombination that can be prepared by ligating with a plasmid DNA having a drug resistance gene that cannot autonomously replicate in the host cell to be introduced.
- a method using homologous recombination frequently used in Escherichia coli for example, a method of introducing recombinant DNA using the homologous recombination system of lambda phage [Proc. Natl. Acad. Sci. USA, 97, 6641-6645 (2000)].
- a selection method utilizing the sucrose sensitivity of Escherichia coli due to the Bacillus subtilis levansucrase integrated on the chromosome together with the recombinant DNA, and a method of incorporating a wild-type rpsL gene into Escherichia coli having a streptomycin-resistant mutant rpsL gene.
- a selection method utilizing the sensitivity of E. coli to streptomycin [Mol. Microbiol. , 55, 137 (2005), Biosci. Biotechnol. Biochem. , 71, 2905 (2007)], etc., to obtain E. coli in which the target region on the chromosomal DNA of the host cell has been replaced with recombinant DNA.
- the transformant obtained by the above method has the DNA of the present invention described in 2 above is, for example, the ability of the transformant to produce GDP-fucose or an acceptor sugar from sugar.
- a transformant obtained by transforming a host cell having can be confirmed by Alternatively, an extract containing the protein of the present invention is prepared from the culture, the extract, GDP-fucose and receptor saccharides are allowed to exist in an aqueous medium, and fucose-containing saccharides accumulated in the aqueous medium. can also be confirmed by comparing the production of .
- transformants of the present invention include the WFL/pAHY2 strain, WFL/pAHY3 strain, WFL/pAHY4 strain and WFL/pAHY5 strain described later in Examples.
- the method for producing the fucose-containing saccharide of the present invention is the method described in 5-1 and 5-2 below.
- Method for Producing Fucose-Containing Carbohydrates by Fermentation comprises culturing the transformant of 4 above in a medium to produce fucose-containing saccharides in the culture.
- a method for producing fucose-containing saccharides by fermentation is mentioned.
- the transformant of the present invention used in the method for producing fucose-containing carbohydrates by fermentation is preferably a transformant capable of producing GDP-fucose from sugar.
- a transformant having the ability to produce an acceptor saccharide may also be used as the transformant of the present invention used in the method for producing a fucose-containing saccharide by fermentation.
- the method for culturing the transformant in 4 above can be carried out according to the usual method used for culturing microorganisms.
- the medium for culturing the transformant should be a medium that contains carbon sources, nitrogen sources, inorganic salts, etc. that can be assimilated by the transformant and that allows efficient culture of the transformant. , both natural and synthetic media may be used.
- Any carbon source can be used as long as it can be assimilated by the transformant.
- sugars such as glucose, fructose, sucrose, molasses containing these, starch or starch hydrolysates, and organic sources such as acetic acid or propionic acid.
- organic sources such as acetic acid or propionic acid.
- acids include acids, alcohols such as glycerol, ethanol, propanol, and the like.
- Nitrogen sources include, for example, ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, and other inorganic or organic acid ammonium salts, other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn steep liquor. , casein hydrolysates, soybean meal, soybean meal hydrolysates, various fermented bacteria and their digests, and the like.
- inorganic salts include monopotassium phosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate.
- Acceptor saccharides such as lactose may be added as fucose-containing saccharide precursors, and GTP, mannose, etc. as GDP-fucose precursors may be added to the medium.
- GDP-fucose may be supplied to the transformant of the present invention by co-cultivating a microorganism capable of producing GDP-fucose from sugar with the transformant of the present invention.
- a microorganism capable of producing GTP may be cultured at the same time.
- microorganisms capable of producing GTP include known microorganisms such as microorganisms in which the expression of enzymes involved in the biosynthetic pathway of GTP is enhanced by various genetic manipulations (Biotechnol Bioeng (2019) Sep 3).
- the transformant to be used does not have the ability to produce receptor carbohydrates such as lactose
- the receptor carbohydrates such as lactose are added to the medium during culture. Add to.
- the transformant to be used does not have the ability to produce receptor carbohydrates such as lactose
- receptor carbohydrates such as lactose can be added during the culture.
- the medium by simultaneously culturing a microorganism capable of producing an acceptor carbohydrate such as lactose from sugar with the transformant of the present invention, the transformant of the present invention accepts lactose and the like.
- Body carbohydrates may be supplied.
- Cultivation is usually preferably carried out under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the culture temperature is usually 15 to 40° C., and the culture time is usually 5 hours to 7 days.
- the pH of the culture solution during cultivation is usually maintained at 3.0 to 9.0.
- the pH is adjusted using an inorganic or organic acid, alkaline solution, urea, calcium carbonate, ammonia, or the like.
- antibiotics such as ampicillin and tetracycline may be added to the medium as necessary during the culture.
- an inducer may be added to the medium as necessary.
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- indole acrylic acid or the like may be added to the medium.
- a fucose-containing saccharide can be produced by producing and accumulating a fucose-containing saccharide in a culture by the above culture and extracting the fucose-containing saccharide from the culture.
- the resulting fucose-containing carbohydrates can be analyzed by conventional methods such as carbohydrate ion chromatography.
- the collection of fucose-containing saccharides from the culture or the treated culture can be carried out by a conventional method using activated charcoal, ion-exchange resin, or the like.
- activated charcoal ion-exchange resin, or the like.
- fucose-containing saccharides accumulate in the cells, for example, the microbial cells are disrupted by ultrasonic waves or the like, and the microbial cells are removed by centrifugation. You can pick quality.
- a culture obtained by culturing the transformant of 4 above or a processed product of the culture is used as an enzyme source, and the enzyme source, GDP-fucose and receptor sugar are present in an aqueous medium. Then, the fucose-containing saccharide is produced and accumulated in the aqueous medium, and the fucose-containing saccharide can be collected from the aqueous medium.
- GDP-fucose and receptor carbohydrates may be of any origin as long as they serve as substrates for the protein of the present invention possessed by the transformant of the present invention.
- the GDP-fucose and receptor saccharides collected from the culture of the microorganism or the processed product of the culture may be used as they are, or the GDP-fucose and the receptor carbohydrates collected from the culture or the processed product of the culture may be used.
- processed cultures include concentrates of cultures, dried cultures, cells obtained by centrifuging cultures, dried cells, lyophilized cells, and Surfactant-treated bacterial cell, ultrasonically treated bacterial cell, mechanical triturated bacterial cell, solvent-treated bacterial cell, enzyme-treated bacterial cell, protein of bacterial cell Fractions, immobilized products of the microbial cells, enzyme preparations obtained by extraction from the microbial cells, and the like can be mentioned.
- aqueous media examples include water, phosphate, carbonate, acetate, borate, citrate, buffers such as Tris, alcohols such as methanol and ethanol, esters such as ethyl acetate, and acetone. and amides such as acetamide.
- the culture solution of the microorganism used as the enzyme source can be used as the aqueous medium.
- the method of analyzing and collecting fucose-containing carbohydrates produced in the aqueous medium is the same as in 5-1.
- Example 1 Construction of microorganisms used for production of 2'-fucosyllactose (1) Obtaining DNA fragments used as markers for gene deletion As such, PCR was performed using the DNA listed in "Template” in Table 1 as a template to obtain each amplified DNA fragment.
- the genomic DNA of 168 strains of Bacillus subtilis was prepared by a standard method.
- the cat of the amplified DNA fragment includes about 200 bp upstream to about 50 bp downstream of the cat gene on pHSG396.
- the amplified DNA fragment sacB contains about 300 bp upstream to about 100 bp downstream of the sacB gene on the genomic DNA of Bacillus subtilis strain 168.
- PCR is performed using DNA consisting of the nucleotide sequences represented by SEQ ID NOS: 15 and 18 as a primer set, and DNA containing the cat gene and the sacB gene (hereinafter referred to as cat -sacB) fragment was obtained.
- lacZ upstream 1 and lacZ upstream 2 comprise approximately 900 bp upstream from the start codon of the lacZ gene.
- lacY downstream 1 and lacY downstream 2 comprise approximately 800 bp downstream from the stop codon of the lacY gene.
- lacZY::cat-sacB A DNA fragment consisting of a sequence in which the cat-sacB fragment was inserted into the sequences of the regions surrounding the lacZ and lacY genes was obtained.
- PCR was performed using a mixture of lacZ upstream 2 and lacY downstream 2 at an equimolar ratio as a template, and DNA consisting of the nucleotide sequences represented by SEQ ID NOS: 20 and 22 as a primer set. , a DNA fragment consisting of a sequence in which the lacZ upstream and the lacY downstream are directly linked (hereinafter referred to as ⁇ lacZY).
- lacZY::cat-sacB fragment was transformed into plasmid pKD46 [Datsenko, K. et al. A. , Warner, B.; L. , Proc. Natl. Acad. Sci. , USA, Vol. 97, 6640-6645 (2000)] was introduced by electroporation into Escherichia coli harboring the lacZ and lacY genes, and a transformant exhibiting chloramphenicol resistance and sucrose sensitivity (lacZ and lacY genes are lacZY::cat -sacB) was obtained.
- the ⁇ lacZY fragment was introduced into Escherichia coli by electroporation into the transformant, resulting in a transformant exhibiting chloramphenicol sensitivity and sucrose resistance (transformant in which lacZY::cat-sacB was replaced with ⁇ lacZY). got From these, a transformant exhibiting ampicillin sensitivity (a transformant lacking pKD46) was obtained.
- the transformant was named ⁇ lacZY.
- PCR was performed using the genomic DNA of Escherichia coli strain KY3591 as a template and DNA consisting of the base sequences shown in "Primer set" in Table 3 as a primer set to obtain each amplified DNA fragment.
- wcaJ upstream 1 and wcaJ upstream 2 comprise approximately 900 bp upstream from the start codon of the wcaJ gene.
- wcaM downstream 1 and wcaM downstream 2 comprise about 800 bp downstream from the stop codon of the wcaM gene.
- PCR was performed using DNAs consisting of the nucleotide sequences represented by SEQ ID NOS: 26 and 28 as a primer set, A DNA fragment (hereinafter referred to as wcaJ-wzxC-wcaKLM::cat-sacB) consisting of a sequence in which the cat-sacB fragment was inserted into the wcaJ-wzxC-wcaKLM operon peripheral region sequence was obtained.
- a mixture of wcaJ upstream 2 and wcaM downstream 2 at an equimolar ratio was used as a template, and PCR was performed using DNA consisting of the nucleotide sequences represented by SEQ ID NOS: 26 and 28 as a primer set to obtain wcaJ-wzxC-wcaKLM.
- a DNA (hereinafter referred to as ⁇ wcaJ-wzxC-wcaKLM) fragment consisting of a sequence in which the wcaJ upstream and the wcaM downstream are directly linked was obtained.
- a transformant (wcaJ-wzxC- A transformant in which wcaKLM was replaced with wcaJ-wzxC-wcaKLM::cat-sacB) was obtained.
- the ⁇ wcaJM fragment was introduced into Escherichia coli by electroporation into the transformant, resulting in a transformant exhibiting chloramphenicol sensitivity and sucrose resistance (wcaJ-wzxC-wcaKLM::cat-sacB was ⁇ wcaJ-wzxC- A transformant substituted with wcaKLM) was obtained. Furthermore, a transformant exhibiting ampicillin sensitivity (a transformant lacking pKD46) was obtained. The transformant was named WFL strain.
- HMFT Helicobacter mustelae-derived ⁇ 1,2-fucosyltransferase
- Genomic DNA of Escherichia coli strain W3110 was prepared by a conventional method.
- the nucleotide sequences represented by SEQ ID NOs: 32 and 33 and SEQ ID NOs: 34 and 35 contain sequences complementary to their 5' ends.
- rcsA-HMFT-lacY A mixture of rcsA, HMFT and lacY fragments at an equimolar ratio was used as a template, and PCR was performed using DNAs consisting of the nucleotide sequences represented by SEQ ID NOs: 37 and 38 as a primer set to obtain a DNA ligated with the three fragments ( hereinafter referred to as rcsA-HMFT-lacY) fragment.
- PCR was performed using plasmid pPE167 (Appl. Obtained.
- nucleotide sequences represented by SEQ ID NOs: 37 and 40 and SEQ ID NOs: 38 and 39 contain sequences complementary to their 5' ends.
- the rcsA-HMFT-lacY fragment obtained above and the vector fragment were ligated using the In-Fusion HD Cloning Kit (manufactured by Takara Bio Inc.) to obtain the expression plasmid pAHY1.
- a plasmid pAHY2 was prepared by introducing all of the five amino acid mutations onto the amino acid sequence of HMFT using a primer set consisting of a DNA consisting of the base sequence represented by .
- a plasmid pAHY3 was created in which the 9th amino acid residue on the HMFT amino acid sequence was mutated.
- a plasmid pAHY4 was prepared by introducing a mutation to the 238th amino acid residue on the HMFT amino acid sequence.
- a plasmid pAHY5 was prepared by introducing mutations to the 9th and 238th amino acid residues on the HMFT amino acid sequence.
- the WFL strain constructed in (2) above was transformed, and WFL/pAHY1 strain, WFL/pAHY2 strain, WFL/ A pAHY3 strain, a WFL/pAHY4 strain, and a WFL/pAHY5 strain were obtained.
- Example 2 Production of 2'-fucosyllactose by fermentation method using microorganism expressing mutant HMFT WFL/pAHY1 strain, WFL/pAHY2 strain, WFL/pAHY3 strain, WFL/pAHY4 obtained in Example 1 and WFL/pAHY5 strains were cultured on LB plates at 30° C. for 24 hours, inoculated into large test tubes containing 5 mL of LB medium containing 100 mg/L kanamycin and shaken at 30° C. for 16 hours. cultured.
- the resulting culture was then transferred to a production medium containing 100 mg/L kanamycin [glucose 30 g/L, lactose monohydrate 5 g/L, magnesium sulfate heptahydrate 2 g/L, dipotassium hydrogen phosphate 16 g/L , potassium dihydrogen phosphate 14 g/L, ammonium sulfate 2 g/L, citric acid monohydrate 1 g/L, casamino acid 5 g/L, thiamine hydrochloride 10 mg/L, ferrous sulfate heptahydrate 50 mg/L, Manganese sulfate pentahydrate 10 mg/L (Other than glucose, lactose monohydrate and magnesium sulfate heptahydrate, it was autoclaved after adjusting the pH to 7.2 with an aqueous sodium hydroxide solution) (Glucose, lactose monohydrate An aqueous solution containing the product and magnesium sulfate hept
- the present invention provides a protein having a modified ⁇ 1,2-fucosyltransferase activity and a method for producing a fucose-containing carbohydrate using the protein or a microorganism capable of producing the protein.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
1.下記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基からなる群より選ばれる1以上のアミノ酸残基から、他のアミノ酸残基への置換を含むアミノ酸配列からなる蛋白質であり、かつ、
元となる下記[1]~[3]のいずれか1に記載の蛋白質に比べてα1,2-フコシルトランスフェラーゼ活性が向上した蛋白質。
[1]配列番号2、4、6、8又は10で表されるアミノ酸配列からなる蛋白質
[2]配列番号2、4、6、8又は10で表されるアミノ酸配列において、1~20個のアミノ酸が欠失、置換、挿入及び/又は付加されたアミノ酸配列からなる変異蛋白質であり、かつ、α1、2-フコシルトランスフェラーゼ活性を有する変異蛋白質
[3]配列番号2、4、6、8又は10で表されるアミノ酸配列と80%以上の同一性を有するアミノ酸配列からなる相同蛋白質であり、かつ、α1、2-フコシルトランスフェラーゼ活性を有する相同蛋白質
2.前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基から、他のアミノ酸残基への置換を含むアミノ酸配列からなる、前記1に記載の蛋白質。
3.前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、以下の〔1a〕~〔1e〕から選ばれる少なくとも1の置換を含むアミノ酸配列からなる、前記1または2に記載の蛋白質。
〔1a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔1d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-スレオニン又はL-セリンへの置換
〔1e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-ロイシン、L-イソロイシン又はL-アラニンへの置換
4.前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、以下の〔2a〕~〔2e〕から選ばれる少なくとも1の置換を含むアミノ酸配列からなる、前記1~3のいずれか1に記載の蛋白質。
〔2a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔2d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-セリンへの置換
〔2e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換
5.前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換を含むアミノ酸配列からなる、前記1~4のいずれか1に記載の蛋白質。
6.前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換を含むアミノ酸配列からなる、前記1~4のいずれか1に記載の蛋白質。
7.前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換、および、配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換を含むアミノ酸配列からなる、前記1~4のいずれか1に記載の蛋白質。
8.前記1~7のいずれか1に記載の蛋白質をコードするDNA。
9.前記8に記載のDNAを含有する組換え体DNA。
10.前記9に記載の組換え体DNAで宿主細胞を形質転換して得られる形質転換体。
11.前記1~7のいずれか1に記載の蛋白質を生産する能力を有する微生物を培地に培養し、培養物中にフコース含有糖質を生成させることを含む、フコース含有糖質の製造法。
12.前記1~7のいずれか1に記載の蛋白質を生産する能力を有する微生物を培地に培養し、得られる培養物又は該培養物の処理物を酵素源として用い、該酵素源、GDP-フコース及び受容体糖質を水性媒体中に存在せしめ、フコース含有糖質を該水性媒体中に生成させることを含む、フコース含有糖質の製造法。
13.前記受容体糖質がラクトースである、前記12に記載のフコース含有糖質の製造法。
14.前記フコース含有糖質が2’-フコシルラクトースである、前記11~13のいずれか1に記載の製造法。
本発明の蛋白質は、以下の(1)~(7)のいずれか1に記載の蛋白質である。
(1)下記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基からなる群より選ばれる1以上のアミノ酸残基から、他のアミノ酸残基への置換を含むアミノ酸配列からなる蛋白質であり、かつ、
元となる[1]~[3]のいずれか1に記載の蛋白質に比べてα1,2-フコシルトランスフェラーゼ活性が向上した蛋白質。
[1]配列番号2、4、6、8又は10で表されるアミノ酸配列からなる蛋白質
[2]配列番号2、4、6、8又は10で表されるアミノ酸配列において、1~20個のアミノ酸が欠失、置換、挿入及び/又は付加されたアミノ酸配列からなる変異蛋白質であり、かつ、α1,2-フコシルトランスフェラーゼ活性を有する変異蛋白質
[3]配列番号2、4、6、8又は10で表されるアミノ酸配列と80%以上の同一性を有するアミノ酸配列からなる相同蛋白質であり、かつ、α1,2-フコシルトランスフェラーゼ活性を有する相同蛋白質
(2)前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基から、他のアミノ酸残基への置換を含むアミノ酸配列からなる、前記(1)に記載の蛋白質。
(3)前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、以下の〔1a〕~〔1d〕から選ばれる少なくとも1の置換を含むアミノ酸配列からなる、前記(1)または(2)に記載の蛋白質。
〔1a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔1d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-スレオニン又はL-セリンへの置換
〔1e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-ロイシン、L-イソロイシン又はL-アラニンへの置換
(4)前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、以下の〔2a〕~〔2e〕から選ばれる少なくとも1の置換を含むアミノ酸配列からなる、前記(1)~(3)のいずれか1に記載の蛋白質。
〔2a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔2d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-セリンへの置換
〔2e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換
(5)前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換を含むアミノ酸配列からなる、前記(1)~(4)のいずれか1に記載の蛋白質。
(6)前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換を含むアミノ酸配列からなる、前記(1)~(4)のいずれか1に記載の蛋白質。
(7)前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換、および配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換を含むアミノ酸配列からなる、前記(1)~(4)のいずれか1に記載の蛋白質。
(i)元となる蛋白質が、配列番号2で表されるアミノ酸配列からなる蛋白質である場合には、それぞれ配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目のアミノ酸残基。
(ii)元となる蛋白質が配列番号4で表されるアミノ酸配列からなる蛋白質である場合には、それぞれ配列番号4で表されるアミノ酸配列の9番目、68番目、75番目、84番目及び243番目のアミノ酸残基。
(iii)元となる蛋白質が配列番号6で表されるアミノ酸配列からなる蛋白質である場合には、それぞれ配列番号6で表されるアミノ酸配列の7番目、66番目、73番目、88番目及び247番目のアミノ酸残基。
(iv)元となる蛋白質が配列番号8で表されるアミノ酸配列からなる蛋白質である場合には、それぞれ配列番号8で表されるアミノ酸配列の7番目、53番目、60番目及び207番目のアミノ酸残基。配列番号8で表されるアミノ酸配列において、配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基は存在しない。
(v)元となる蛋白質が配列番号10で表されるアミノ酸配列からなる蛋白質である場合には、それぞれ配列番号10で表されるアミノ酸配列の7番目、66番目、73番目、82番目及び238番目のアミノ酸残基。
A群:ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、o-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン
B群:アスパラギン酸、グルタミン酸、イソアスパラギン酸、イソグルタミン酸、2-アミノアジピン酸、2-アミノスベリン酸
C群:アスパラギン、グルタミン
D群:リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸
E群:プロリン、3-ヒドロキシプロリン、4-ヒドロキシプロリン
F群:セリン、スレオニン、ホモセリン
G群:フェニルアラニン、チロシン
〔a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基の前記D群に記載のアミノ酸残基(リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸)から選ばれる1への置換
〔b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基の前記D群に記載のアミノ酸残基(リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸)から選ばれる1への置換
〔c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基の前記E群に記載のアミノ酸残基(プロリン、3-ヒドロキシプロリン、4-ヒドロキシプロリン)から選ばれる1への置換
〔d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基の前記F群に記載のアミノ酸残基(セリン、スレオニン、ホモセリン)から選ばれる1への置換
〔e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基の前記A群に記載のアミノ酸残基(ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、o-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン)から選ばれる1への置換
〔1a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔1d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-スレオニン又はL-セリンへの置換
〔1e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-ロイシン、L-イソロイシン又はL-アラニンへの置換
〔2a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔2d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-セリンへの置換
〔2e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換
〔A〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基から、他のアミノ酸への置換、好ましくは前記D群に記載のアミノ酸残基(リジン、アルギニン、オルニチン、2,4-ジアミノブタン酸、2,3-ジアミノプロピオン酸)から選ばれる1への置換、より好ましくはL-アルギニンへの置換
〔B〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基から、他のアミノ酸への置換、好ましくは前記A群に記載のアミノ酸残基(ロイシン、イソロイシン、ノルロイシン、バリン、ノルバリン、アラニン、2-アミノブタン酸、メチオニン、o-メチルセリン、t-ブチルグリシン、t-ブチルアラニン、シクロヘキシルアラニン)から選ばれる1への置換、より好ましくはL-アラニンへの置換
〔C〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基からL-アルギニンへの置換、および配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基からL-アラニンへの置換
本発明のDNAは、上記(1)~(7)のいずれか1に記載の蛋白質をコードするDNAである。本発明のDNAとして、具体的には以下の(8)~(13)のいずれか1のDNAが挙げられる。
(8)下記[4]~[6]のいずれか1に記載のDNAでコードされる蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基からなる群より選ばれる1以上のアミノ酸残基が、他のアミノ酸残基に置換されたアミノ酸配列からなる蛋白質をコードするDNA。
[4]配列番号1、3、5、7又は9で表される塩基配列からなるDNA
[5]配列番号1、3、5、7又は9で表される塩基配列と相補的な塩基配列からなるDNAとストリンジェントな条件下でハイブリダイズし、かつ、α1,2-フコシルトランスフェラーゼ活性を有する相同蛋白質をコードするDNA
[6]配列番号1、3、5、7又は9で表される塩基配列と少なくとも95%以上、好ましくは97%以上、さらに好ましくは98%以上、最も好ましくは99%以上の同一性を有する塩基配列からなり、かつ、α1,2-フコシルトランスフェラーゼ活性を有する相同蛋白質をコードするDNA
(9)上記(8)に記載のDNAであって、そのコードするアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基がL-アルギニン、68番目に対応するアミノ酸残基がL-アルギニン、75番目に対応するアミノ酸残基がL-プロリン、86番目に対応するアミノ酸残基がL-セリン又は238番目に対応するアミノ酸残基がL-アラニンに置換されたアミノ酸配列からなる蛋白質をコードするDNA。
(10)上記(8)に記載のDNAであって、そのコードするアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基がL-アルギニンに置換されたアミノ酸配列からなる蛋白質をコードするDNA。
(11)上記(8)に記載のDNAであって、そのコードするアミノ酸配列において、配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基がL-アラニンに置換されたアミノ酸配列からなる蛋白質をコードするDNA。
(12)上記(8)に記載のDNAであって、そのコードするアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基がL-アルギニンに、かつ、238番目に対応するアミノ酸残基がL-アラニンに置換されたアミノ酸配列からなる蛋白質をコードするDNA。
(13)配列番号11、12、13又は14で表される塩基配列を有するDNA。
本発明の組換え体DNAは、宿主細胞において自律複製可能なDNAであって、前記2の本発明のDNAを転写できる位置にプロモーターを含有している発現ベクターに本発明のDNAが組み込まれているDNAである。
本発明の形質転換体は、前記2に記載の本発明のDNAを含有する組換え体DNAで宿主細胞を形質転換して得られる形質転換体である。
本発明のフコース含有糖質の製造法は、以下の5-1及び5-2に記載の方法である。
本発明のフコース含有糖質の製造法としては、上記4の形質転換体を培地に培養し、培養物中にフコース含有糖質を生成させることを含む、発酵法によるフコース含有糖質の製造法が挙げられる。
本発明のフコース含有糖質の製造法としては、また、GDP-フコース及び受容体糖質を前駆体として用いるフコース含有糖質の製造法が挙げられる。
実施例において、2’-フコシルラクトースの分析、定量は以下に示す手順で行った。培養後の微生物を含む培養液を遠心分離し、上清を回収した。該上清に含まれる2’-フコシルラクトースを糖分析装置ICS-5000(サーモフィッシャーサイエンティフィック社製)にて分析した。
カラム:CarboPAC PA1
カラム温度:25℃
移動相: (移動相A)水
(移動相B)500mmol/L 水酸化ナトリウム
(移動相C)300mmol/L 酢酸ナトリウム
移動相A、移動相B及び移動相Cの混合比:
(0~10分) 80:20:0から70:20:10の勾配
(10~18分) 70:20:10
(18~25分) 80:20:0
流速:0.8mL/min
検出器:パルスドアンペロメトリー検出器
(1)遺伝子欠損の際にマーカーとして用いるDNA断片の取得
表1の「プライマーセット」で表わされる塩基配列からなるDNAをプライマーセットとして、表1の「鋳型」に記載されたDNAを鋳型としてPCRを行い、各増幅DNA断片を得た。
β-ガラクトシダーゼをコードするDNA(以下、lacZ遺伝子という。)、ラクトースパーミアーゼをコードするDNA(以下、lacY遺伝子という。)及びコラン酸生成関連蛋白質をコードするDNA(以下、wcaJ、wzxC、wcaK、wcaL、又はwcaM遺伝子という。)を欠損した大腸菌を、以下の方法で造成した。なお、lacZ及びlacY(以下、lacZYという。)、ならびに、wcaJ、wzxC、wcaK、wcaL、及びwcaM(以下、wcaJ-wzxC-wcaKLMという。)は大腸菌ゲノム上でそれぞれオペロンを形成している。
表4の「プライマーセット」で表される塩基配列からなるDNAをプライマーセットとして、表4の「鋳型」に記載されたDNAを鋳型としてPCRを行い、各増幅DNA断片を得た。
上記(3)で得られたプラスミドpAHY1を鋳型とし、Prime STAR Mutagenesis Basal Kit(タカラバイオ社製)を用いて、表5に記載の「プライマーセット」で表される塩基配列からなるDNAをプライマーセットとして、HMFTのアミノ酸配列上に当該5つのアミノ酸変異を全て導入したプラスミドpAHY2を作製した。
実施例1で得られたWFL/pAHY1株、WFL/pAHY2株、WFL/pAHY3株、WFL/pAHY4株、及びWFL/pAHY5株を、LBプレート上で30℃にて24時間培養し、100mg/Lのカナマイシンを含むLB培地5mLが入った大型試験管に植菌して30℃で16時間、振盪培養した。その後、得られた培養液を100mg/Lのカナマイシンを含む生産培地[グルコース30g/L、ラクトース一水和物5g/L、硫酸マグネシウム七水和物2g/L、リン酸水素二カリウム16g/L、リン酸二水素カリウム14g/L、硫酸アンモニウム2g/L、クエン酸一水和物1g/L、カザミノ酸5g/L、チアミン塩酸塩10mg/L、硫酸第一鉄七水和物50mg/L、硫酸マンガン五水和物10mg/L(グルコース、ラクトース一水和物及び硫酸マグネシウム七水和物以外については、水酸化ナトリウム水溶液によりpH7.2に調整した後オートクレーブした)(グルコース、ラクトース一水和物及び硫酸マグネシウム七水和物含有水溶液は別途調製した後オートクレーブし、それぞれ冷却後、混合した)]が5mL入った大型試験管に0.1mL植菌し、30℃で30時間振盪培養した。
Claims (14)
- 下記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基からなる群より選ばれる1以上のアミノ酸残基から、他のアミノ酸残基への置換を含むアミノ酸配列からなる蛋白質であり、かつ、
元となる下記[1]~[3]のいずれか1に記載の蛋白質に比べてα1,2-フコシルトランスフェラーゼ活性が向上した蛋白質。
[1]配列番号2、4、6、8又は10で表されるアミノ酸配列からなる蛋白質
[2]配列番号2、4、6、8又は10で表されるアミノ酸配列において、1~20個のアミノ酸が欠失、置換、挿入及び/又は付加されたアミノ酸配列からなる変異蛋白質であり、かつ、α1、2-フコシルトランスフェラーゼ活性を有する変異蛋白質
[3]配列番号2、4、6、8又は10で表されるアミノ酸配列と80%以上の同一性を有するアミノ酸配列からなる相同蛋白質であり、かつ、α1、2-フコシルトランスフェラーゼ活性を有する相同蛋白質 - 前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目、68番目、75番目、86番目及び238番目に対応するアミノ酸残基から、他のアミノ酸残基への置換を含むアミノ酸配列からなる、請求項1に記載の蛋白質。
- 前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、以下の〔1a〕~〔1e〕から選ばれる少なくとも1の置換を含むアミノ酸配列からなる、請求項1または2に記載の蛋白質。
〔1a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-リジン又はL-アルギニンへの置換
〔1c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔1d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-スレオニン又はL-セリンへの置換
〔1e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-ロイシン、L-イソロイシン又はL-アラニンへの置換 - 前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、以下の〔2a〕~〔2e〕から選ばれる少なくとも1の置換を含むアミノ酸配列からなる、請求項1~3のいずれか1項に記載の蛋白質。
〔2a〕配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2b〕配列番号2で表されるアミノ酸配列の68番目に対応するアミノ酸残基のL-アルギニンへの置換
〔2c〕配列番号2で表されるアミノ酸配列の75番目に対応するアミノ酸残基のL-プロリンへの置換
〔2d〕配列番号2で表されるアミノ酸配列の86番目に対応するアミノ酸残基のL-セリンへの置換
〔2e〕配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換 - 前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換を含むアミノ酸配列からなる、請求項1~4のいずれか1項に記載の蛋白質。
- 前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換を含むアミノ酸配列からなる、請求項1~4のいずれか1項に記載の蛋白質。
- 前記[1]~[3]のいずれか1に記載の蛋白質のアミノ酸配列において、配列番号2で表されるアミノ酸配列の9番目に対応するアミノ酸残基のL-アルギニンへの置換、および、配列番号2で表されるアミノ酸配列の238番目に対応するアミノ酸残基のL-アラニンへの置換を含むアミノ酸配列からなる、請求項1~4のいずれか1項に記載の蛋白質。
- 請求項1~7のいずれか1項に記載の蛋白質をコードするDNA。
- 請求項8に記載のDNAを含有する組換え体DNA。
- 請求項9に記載の組換え体DNAで宿主細胞を形質転換して得られる形質転換体。
- 請求項1~7のいずれか1項に記載の蛋白質を生産する能力を有する微生物を培地に培養し、培養物中にフコース含有糖質を生成させることを含む、フコース含有糖質の製造法。
- 請求項1~7のいずれか1項に記載の蛋白質を生産する能力を有する微生物を培地に培養し、得られる培養物又は該培養物の処理物を酵素源として用い、該酵素源、GDP-フコース及び受容体糖質を水性媒体中に存在せしめ、フコース含有糖質を該水性媒体中に生成させることを含む、フコース含有糖質の製造法。
- 前記受容体糖質がラクトースである、請求項12に記載のフコース含有糖質の製造法。
- 前記フコース含有糖質が2’-フコシルラクトースである、請求項11~13のいずれか1項に記載のフコース含有糖質の製造法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22756311.1A EP4296360A1 (en) | 2021-02-19 | 2022-02-18 | Modified protein having alpha1,2-fucosyltransferase activity and method for producing fucose-containing carbohydrate |
JP2023500951A JPWO2022176994A1 (ja) | 2021-02-19 | 2022-02-18 | |
CN202280015879.XA CN117157403A (zh) | 2021-02-19 | 2022-02-18 | 经改造的具有α1,2-岩藻糖基转移酶活性的蛋白质和含有岩藻糖的糖质的制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021025170 | 2021-02-19 | ||
JP2021-025170 | 2021-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022176994A1 true WO2022176994A1 (ja) | 2022-08-25 |
Family
ID=82930662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/006790 WO2022176994A1 (ja) | 2021-02-19 | 2022-02-18 | 改変されたα1,2-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4296360A1 (ja) |
JP (1) | JPWO2022176994A1 (ja) |
CN (1) | CN117157403A (ja) |
WO (1) | WO2022176994A1 (ja) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
WO2001077313A1 (fr) * | 2000-04-11 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | α1,2-FUCOSYLTRANSFERASE ET PROCEDE SERVANT A PREPARER UN GLUCIDE COMPLEXE CONTENANT FUCOSE |
JP2002528122A (ja) * | 1998-11-04 | 2002-09-03 | ガバナーズ オブ ザ ユニバーシティー オブ アルバータ | ヘリコバクター・ピロリ由来α1,2−フコシルトランスフェラーゼ |
WO2003018794A1 (en) * | 2001-08-24 | 2003-03-06 | Kyowa Hakko Kogyo Co., Ltd. | α-1,2-FUCOSYL TRANSFERASE AND DNA ENCODING THE SAME |
JP2015529453A (ja) * | 2012-07-25 | 2015-10-08 | グリコシン リミテッド ライアビリティー カンパニー | フコシル化オリゴ糖の生産における使用に適したアルファ(1,2)フコシルトランスフェラーゼ |
JP2021025170A (ja) | 2019-08-06 | 2021-02-22 | 株式会社明光商会 | 裁断ユニット、タイルカーペット解体システム、及びタイルカーペット解体方法 |
-
2022
- 2022-02-18 EP EP22756311.1A patent/EP4296360A1/en active Pending
- 2022-02-18 JP JP2023500951A patent/JPWO2022176994A1/ja active Pending
- 2022-02-18 WO PCT/JP2022/006790 patent/WO2022176994A1/ja active Application Filing
- 2022-02-18 CN CN202280015879.XA patent/CN117157403A/zh active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57134500A (en) | 1981-02-12 | 1982-08-19 | Kyowa Hakko Kogyo Co Ltd | Plasmid pcg1 |
JPS57183799A (en) | 1981-04-17 | 1982-11-12 | Kyowa Hakko Kogyo Co Ltd | Novel plasmid |
JPS5835197A (ja) | 1981-08-26 | 1983-03-01 | Kyowa Hakko Kogyo Co Ltd | プラスミドpcg2 |
JPS58105999A (ja) | 1981-12-17 | 1983-06-24 | Kyowa Hakko Kogyo Co Ltd | 新規ベクタ−プラスミド |
JPS63233798A (ja) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | 5′−グアニル酸の製造法 |
JPS63248394A (ja) | 1987-04-06 | 1988-10-14 | Kyowa Hakko Kogyo Co Ltd | 核酸関連物質の製造法 |
WO1998012343A1 (fr) | 1996-09-17 | 1998-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Procedes de production de nucleotides de sucre et de glucides complexes |
JP2002528122A (ja) * | 1998-11-04 | 2002-09-03 | ガバナーズ オブ ザ ユニバーシティー オブ アルバータ | ヘリコバクター・ピロリ由来α1,2−フコシルトランスフェラーゼ |
WO2001077313A1 (fr) * | 2000-04-11 | 2001-10-18 | Kyowa Hakko Kogyo Co., Ltd. | α1,2-FUCOSYLTRANSFERASE ET PROCEDE SERVANT A PREPARER UN GLUCIDE COMPLEXE CONTENANT FUCOSE |
WO2003018794A1 (en) * | 2001-08-24 | 2003-03-06 | Kyowa Hakko Kogyo Co., Ltd. | α-1,2-FUCOSYL TRANSFERASE AND DNA ENCODING THE SAME |
JP4048173B2 (ja) | 2001-08-24 | 2008-02-13 | 協和醗酵工業株式会社 | α1,2−フコース転移酵素および該酵素をコードするDNA |
JP2015529453A (ja) * | 2012-07-25 | 2015-10-08 | グリコシン リミテッド ライアビリティー カンパニー | フコシル化オリゴ糖の生産における使用に適したアルファ(1,2)フコシルトランスフェラーゼ |
JP2021025170A (ja) | 2019-08-06 | 2021-02-22 | 株式会社明光商会 | 裁断ユニット、タイルカーペット解体システム、及びタイルカーペット解体方法 |
Non-Patent Citations (28)
Title |
---|
"Immunology methods manual", 1997, ACADEMIC PRESS |
"Methods for General and Molecular Bacteriology", 1994, ASM PRESS |
"Molecular Cloning", 2012, COLD SPRING HARBOR LABORATORY PRESS |
APPL. ENVIRON. MICROBIOL., vol. 73, 2007, pages 6378 - 6385 |
APPL. MICROBIOL. BIOTECHNOL., vol. 53, 2000, pages 674 - 679 |
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 20, 2007, pages 6378 - 6385 |
BIOSCI. BIOTECHNOL. BIOCHEM., vol. 71, 2007, pages 2905 |
BIOTECHNOL BIOENG, 3 September 2019 (2019-09-03) |
CURR OPIN BIOTECHNOL, vol. 56, 2019, pages 130 - 137 |
DATSENKO, K. A.WARNER, B. L. L., PROC. NATL. ACAD.SCI, USA, vol. 97, 2000, pages 6640 - 6645 |
GENE, vol. 33, 1985, pages 103 |
J BIOTECHNOL, vol. 235, 2016, pages 61 - 83 |
J. BACTERIOL., vol. 153, 1983, pages 163 |
J. MOL. BIOL., vol. 215, 1990, pages 403 |
JOURNAL OF BIOTECHNOLOGY, vol. 257, 2017, pages 192 - 198 |
METABOLIC ENGINEERING, vol. 41, 2017, pages 23 - 38 |
METHODS ENZYMOL., vol. 183, 1990, pages 63 |
MICROB CELL FACT, vol. 12, 2013, pages 40 |
MOL. MICROBIOL., vol. 55, 2005, pages 137 |
MOLECULAR AND GENERAL GENETICS, vol. 196, 1984, pages 175 |
NUCLEIC ACIDS RES., vol. 16, 1988, pages 6127 |
NUCLEIC ACIDS RES., vol. 18, 1990, pages 6069 |
PRO. NAT. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
PROC. NAT. ACAD. SCI., USA, vol. 74, 1977, pages 5463 |
PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 6641 - 6645 |
PROC. NATL. ACAD. SCI., USA, vol. 69, 1972, pages 2110 |
PROC. NATL. ACAD. SCI., USA, vol. 81, 1984, pages 4889 |
PROC. NATL. ACAD. SCI., USA, vol. 82, 1985, pages 4306 |
Also Published As
Publication number | Publication date |
---|---|
CN117157403A (zh) | 2023-12-01 |
JPWO2022176994A1 (ja) | 2022-08-25 |
EP4296360A1 (en) | 2023-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7244613B2 (ja) | 希少糖の製造法 | |
JP7035024B2 (ja) | テアニンの製造方法 | |
JP2016013141A (ja) | 有用物質の製造法 | |
WO2022168992A1 (ja) | 1,3-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 | |
WO2023238843A1 (ja) | 3'-シアリルラクトースの生産性が向上した微生物および3'-シアリルラクトースの製造方法 | |
JP5592059B2 (ja) | L−グルタミンの製造法 | |
WO2022168991A1 (ja) | フコース含有糖質の輸送活性を有する蛋白質及びフコース含有糖質の製造法 | |
WO2022176994A1 (ja) | 改変されたα1,2-フコシルトランスフェラーゼ活性を有する蛋白質及びフコース含有糖質の製造法 | |
JP6441806B2 (ja) | N−アセチルノイラミン酸及びn−アセチルノイラミン酸含有糖質の製造法 | |
WO2023153461A1 (ja) | ルイスx骨格を有するオリゴ糖の製造法 | |
JP6086678B2 (ja) | ホモアミノ酸の製造法 | |
WO2023182528A1 (ja) | α1,2-フコシルトランスフェラーゼ活性を有する蛋白質及びラクト-N-フコペンタオースI(LNFPI)の製造方法 | |
WO2023120615A1 (ja) | コア3糖としてラクト-n-トリオースiiを含む糖質の製造方法および該糖質の結晶の製造方法 | |
EP4400588A1 (en) | Recombinant microorganism used for producing cdp-choline, and method for producing cdp-choline using said recombinant microorganism | |
WO2021125245A1 (ja) | 改変されたラクトースパーミアーゼを有する微生物及びラクトース含有オリゴ糖の製造法 | |
US7445915B2 (en) | Mutant isopropylmalate isomerase | |
WO2023182527A1 (ja) | ラクトジフコテトラオース(ldft)の製造法 | |
WO2023058772A1 (ja) | N-アセチルノイラミン酸及び/又はn-アセチルノイラミン酸含有糖質の生産能を有する微生物及び該微生物を用いたn-アセチルノイラミン酸及び/又はn-アセチルノイラミン酸含有糖質の製造方法 | |
WO2021261564A1 (ja) | ジペプチドの製造法 | |
JP2022001556A (ja) | 蛋白質及び3−ヒドロキシイソ吉草酸の製造方法 | |
WO2023210244A1 (ja) | Nampt活性を有する蛋白質およびnmnの製造方法 | |
EP2522738A1 (en) | Process for production of l-glutamine or l-glutamic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22756311 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023500951 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18547082 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022756311 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022756311 Country of ref document: EP Effective date: 20230919 |